|
|
|
| Alzheimer disease - new drugs, markets and companies |
|
| Table of Contents Published: 2009/11 |
| Alzheimer' s disease remains a challenge in management. With nearly 8 million sufferers from this condition in the seven major markets of the world and anticipated increases in the future. Considerable research is in progress to understand the pathomechan ... |
| Biomarkers - technologies,markets and companies |
|
| Table of Contents Published: 2009/11 |
| This report follows the broad definition of a biomarker as a characteristic that can be objectively measured and evaluated as an indicator of normal biological or pathogenic processes as well as pharmacological responses to a therapeutic intervention. Tes ... |
| Cell Therapy - Technologies, Markets and Companies |
|
| Table of Contents Published: 2009/11 |
| This report describes and evaluates cell therapy technologies and methods, which have already started to play an important role in the practice of medicine. Hematopoietic stem cell transplantation is replacing the old fashioned bone marrow transplants. Ro ... |
| Cytogenetics - technologies,markets and companies |
|
| Table of Contents Published: 2009/11 |
| This report deals with cytogenetics in a broader sense rather than the classical use mainly to describe the chromosome structure and identify abnormalities related to disease. In the age of molecular biology, it is also referred to as molecular cytogeneti ... |
| DNA sequencing: technologies, markets and companies |
|
| Table of Contents Published: 2009/11 |
| This report briefly reviews development of sequencing technologies, current large and small sequencers as well as companies developing them. Companies developing software for analysis of sequencing data are listed. Selected academic institutes conducting ... |
| Gene Therapy - technologies, markets and companies |
|
| Table of Contents Published: 2009/11 |
| Gene therapy can be broadly defined as the transfer of defined genetic material to specific target cells of a patient for the ultimate purpose of preventing or altering a particular disease state. Genes and DNA are now being introduced without the use of ... |
| Neuroprotection - Drugs, Markets and Companies |
|
| Table of Contents Published: 2009/11 |
| This report describes the role of neuroprotection in acute disorders such as stroke and injuries of the nervous system as well as in chronic diseases such as neurodegenerative disorders because many of the underlying mechanisms of damage to neural tissues ... |
| Nitric Oxide - Therapeutics, Markets and Companies |
|
| Table of Contents Published: 2009/11 |
| This report describes the latest concepts of the role of nitric oxide (NO) in health and disease as a basis for therapeutics and development of new drugs. Major segments of the market for nitric oxide-based drugs are described as well as the companies inv ... |
| Pain Therapeutics - Drugs, Markets and Companies |
|
| Table of Contents Published: 2009/11 |
| This report describes the latest concepts of pathomechanisms of pain as a basis for management and development of new pharmacotherapies for pain. Major segments of the pain market are arthritis, neuropathic pain and cancer pain. Because pain is a subjecti ... |
| RNAi - technologies, markets and companies |
|
| Table of Contents Published: 2009/11 |
| RNA interference (RNAi) or gene silencing involves the use of double stranded RNA (dsRNA). Once inside the cell, this material is processed into short 21-23 nucleotide RNAs termed siRNAs that are used in a sequence-specific manner to recognize and destroy ... |
|
 Top
|
|
View Cart
